Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price objective upped by research analysts at Wells Fargo & Company from $105.00 to $120.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 13.25% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Truist Financial upped their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. BMO Capital Markets upped their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Finally, Barclays upped their price objective on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $101.33.

Gilead Sciences Trading Up 2.6 %

NASDAQ GILD opened at $105.96 on Wednesday. The stock has a market capitalization of $132.05 billion, a price-to-earnings ratio of 1,177.33, a PEG ratio of 1.25 and a beta of 0.18. The stock’s 50 day moving average price is $93.38 and its two-hundred day moving average price is $87.24. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $106.43.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. As a group, analysts anticipate that Gilead Sciences will post 4.35 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 137,676 shares of the company’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total value of $14,073,240.72. Following the sale, the chief financial officer now owns 171,223 shares of the company’s stock, valued at approximately $17,502,415.06. The trade was a 44.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 710,500 shares of company stock worth $67,684,956. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Gilead Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. nVerses Capital LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $25,000. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the last quarter. Valued Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the 4th quarter worth $28,000. Finally, Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth $29,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.